Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acetylator polymorphism in multiple sclerosis

J M Ladero1, R Arroyo, C De Andrés

  • 1Gastroenterology Service, Hospital Universitario San Carlos, University Complutense, Department of Medicine, Madrid, Spain.

Acta Neurologica Scandinavica
|February 1, 1994
PubMed
Summary

Genetic polymorphic acetylation, a metabolic trait, does not appear to increase the risk for developing multiple sclerosis (MS). This study found no significant association between slow acetylator status and MS susceptibility or age of disease onset.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-generation merozoites of caprine <i>Eimeria christenseni</i> are capable to invade and egress primary host endothelial cells <i>in vitro</i>.

Frontiers in veterinary science·2025
Same author

[Cadmium polyneuropathy: a rare, but not less important, cause of peripheral neuropathy].

Revista de neurologia·2022
Same author

Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-β therapy.

Neurologia·2022
Same author

Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-β therapy.

Neurologia·2021
Same author

Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and meta-analysis. Response to letter to the editor by Zheng et al.

European journal of neurology·2020
Same author

Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and meta-analysis.

European journal of neurology·2020

Area of Science:

  • Pharmacogenetics
  • Neuroimmunology
  • Human Genetics

Background:

  • Genetic factors play a role in the susceptibility to multiple sclerosis (MS).
  • Acetylation polymorphism, a variation in drug metabolism, is a potential genetic marker.
  • The link between acetylation capacity and MS risk remains unclear.

Purpose of the Study:

  • To investigate the association between genetic polymorphic acetylation and the risk of developing multiple sclerosis.
  • To determine if slow acetylator phenotype is a risk factor for MS.
  • To explore the relationship between acetylator polymorphism and age at disease onset in MS patients.

Main Methods:

  • Determined acetylator polymorphism using sulphamethazine in 71 MS patients and 268 controls.
  • Classified individuals as slow or fast acetylators based on metabolic profiles.

Related Experiment Videos

  • Compared the prevalence of slow acetylators between MS patients and the control group.

    • Main Results:

    • No significant difference in the proportion of slow acetylators was observed between MS patients (52.1%) and controls (56.3%).
    • The prevalence of slow acetylator phenotype did not correlate with an increased risk for multiple sclerosis.
    • No association was found between acetylator polymorphism and the age at disease onset in the studied MS cohort.

    Conclusions:

    • The findings do not support a relationship between genetic polymorphic acetylation and the risk for multiple sclerosis.
    • Acetylation capacity, as determined by sulphamethazine metabolism, does not appear to be a significant genetic risk factor for MS.
    • Further research may explore other genetic polymorphisms in relation to MS susceptibility.